CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 (TLR7) and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates. The paper entitled “Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-like Receptors 7 and 8” is published in the June issue of Molecular Cancer Therapeutics (Vol. 9: 1788, 2010) and is authored by Idera scientists.
